Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorized
  2. c-icon icon-chevron-right
June 25, 2020

Dexamethasone, an unexpected drug, shows promise in treating Covid-19

By Victoria Smith

At present, there are more than 2,200 clinical trials attempting to find a Covid-19 vaccine or therapy. The National Institute of Health recently stopped its hydroxychloroquine clinical trial, concluding that there was no real benefit for affected individuals. Dexamethasone, however, recently highlighted positive preliminary results from the RECOVERY (Randomised Evaluation of COVid-19 thERapY) clinical trial.

The UK RECOVERY trial is a Phase II/III randomised, controlled trial, which commenced in March 2020 and is testing numerous potential treatments for Covid-19. Read more here.

Related Companies

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU